News Releases

Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year Full Year 2023 International

Worldwide revenue of $98.3 million – an increase of 18.1% year over year U.S. revenue of $81.7 million – an increase of 17.1% year over year International revenue of $16.6 million – an increase of 23.2% year over year Net loss of $9.1 million – an improvement of $3.2 million year over year Positive

Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvement of $9.7 million year over year

Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Jan. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc.

MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief

MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms.